Kwon Janice S, Elit Laurie, Finn Martha, Hirte Holger, Mazurka John, Moens Francois, Trim Kristina
Division of Gynecologic Oncology, University of Toronto, Toronto, Ontario, M5S 1A1, Canada.
Gynecol Oncol. 2002 Mar;84(3):420-5. doi: 10.1006/gyno.2001.6546.
The aim of this study was to compare the rates of hypersensitivity reactions to paclitaxel with the conventional prophylactic regimen of two doses of oral corticosteroids and a modified regimen of a single dose of intravenous corticosteroid.
This was a retrospective historical cohort study assessing the rates of hypersensitivity reactions in patients receiving paclitaxel for ovarian or primary peritoneal carcinoma at the Hamilton Regional Cancer Centre from 1996 to 2000. Until 1998, all patients received the conventional prophylactic regimen consisting of two doses of oral dexamethasone (20 mg), 12 and 6 h prior to paclitaxel. From 1998 to the present, patients received a single dose of intravenous dexamethasone (20 mg), 30 min prior to paclitaxel. All patients also received an H(1) and H(2) blocker intravenously prior to paclitaxel administration. The analysis was corrected for potential covariates such as dose of paclitaxel and rate of infusion. The primary outcome measure was the rate of hypersensitivity reactions as defined by the National Cancer Institute of Canada-Clinical Trials Group. The Yates-corrected chi(2) test was used to compare the rates of these reactions, and a logistic regression analysis was used to determine whether any of the covariates were significant factors in these reactions.
One hundred seven patients received the conventional corticosteroid prophylaxis prior to paclitaxel, and 110 received the single-dose intravenous corticosteroid prophylaxis. Of the 107 patients in the conventional prophylaxis group, 8 had a hypersensitivity reaction (7.5%), and only 1 of these was severe (0.9%). In contrast, of the 110 patients in the single-dose IV corticosteroid group, 19 had a hypersensitivity reaction (17.3%), and 8 of these were severe (7.3%). The difference in hypersensitivity reaction rates was significant (chi(2), P = 0.047). In the logistic regression analysis, the only significant factor related to hypersensitivity reactions was the type of prophylactic steroid regimen.
In this series, the single-dose intravenous corticosteroid prophylactic regimen appeared to be associated with a higher rate of hypersensitivity reactions to paclitaxel than the conventional two-dose oral corticosteroid regimen.
本研究旨在比较紫杉醇过敏反应发生率,比较对象为采用两剂口服糖皮质激素的传统预防方案及单剂静脉注射糖皮质激素的改良方案。
这是一项回顾性历史队列研究,评估1996年至2000年在汉密尔顿地区癌症中心接受紫杉醇治疗卵巢癌或原发性腹膜癌患者的过敏反应发生率。直到1998年,所有患者均接受传统预防方案,即紫杉醇给药前12小时和6小时口服两剂地塞米松(20毫克)。从1998年至今,患者在紫杉醇给药前30分钟接受单剂静脉注射地塞米松(20毫克)。所有患者在紫杉醇给药前还静脉注射了一种H(1)和H(2)阻滞剂。分析针对潜在协变量进行了校正,如紫杉醇剂量和输注速率。主要结局指标是加拿大国家癌症研究所-临床试验组定义的过敏反应发生率。采用Yates校正卡方检验比较这些反应的发生率,并采用逻辑回归分析确定任何协变量是否为这些反应的显著因素。
107例患者在紫杉醇给药前接受传统糖皮质激素预防,110例接受单剂静脉注射糖皮质激素预防。在传统预防组的107例患者中,8例发生过敏反应(7.5%),其中只有1例严重(0.9%)。相比之下,在单剂静脉注射糖皮质激素组的110例患者中,19例发生过敏反应(17.3%),其中8例严重(7.3%)。过敏反应发生率差异有统计学意义(卡方检验,P = 0.047)。在逻辑回归分析中,与过敏反应相关的唯一显著因素是预防性糖皮质激素方案的类型。
在本系列研究中,单剂静脉注射糖皮质激素预防方案似乎比传统的两剂口服糖皮质激素方案导致更高的紫杉醇过敏反应发生率。